Good Manufacturing Practice Considerations for Responding to COVID-19 Infection in Employees in Drug and Biological Products Manufacturing : Guidance for Industry | NLM

Disaster Information Management Research Center | NLM

Good Manufacturing Practice Considerations for Responding to COVID-19 Infection in Employees in Drug and Biological Products Manufacturing : Guidance for Industry

06/19/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 6/19/2020. The Food and Drug Administration has issued this 13-page guidance to provide recommendations to drug and biological product manufacturers regarding manufacturing controls to prevent contamination of drugs; risk assessment of SARS-CoV-2 as it relates to drug safety or quality; and continuity of manufacturing operations during the COVID-19 pandemic. (PDF)